we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Company profile
Ticker
VTGN
Exchange
Website
CEO
Shawn K. Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Excaliber Enterprises, Ltd.
SEC CIK
Corporate docs
Subsidiaries
Vistastem, Inc. • Pherin Pharmaceuticals, Inc. ...
IRS number
205093315
VTGN stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
1 Mar 24
S-3
Shelf registration
13 Feb 24
8-K
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
13 Feb 24
10-Q
2024 Q3
Quarterly report
13 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
3 Jan 24
10-Q
2024 Q2
Quarterly report
9 Nov 23
8-K
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
9 Nov 23
8-K/A
Other Events
6 Nov 23
8-K
Other Events
6 Nov 23
Transcripts
VTGN
Earnings call transcript
2024 Q3
13 Feb 24
VTGN
Earnings call transcript
2024 Q2
9 Nov 23
VTGN
Earnings call transcript
2024 Q1
10 Aug 23
VTGN
Earnings call transcript
2023 Q3
7 Feb 23
VTGN
Earnings call transcript
2023 Q2
11 Nov 22
VTGN
Earnings call transcript
2023 Q1
12 Aug 22
VTGN
Earnings call transcript
2022 Q4
24 Jun 22
VTGN
Earnings call transcript
2022 Q3
11 Feb 22
VTGN
Earnings call transcript
2022 Q2
11 Nov 21
VTGN
Earnings call transcript
2022 Q1
12 Aug 21
Latest ownership filings
4
Mary L. Rotunno
6 Mar 24
4
JERRY B GIN
6 Mar 24
4
Margaret M FitzPatrick
6 Mar 24
4
Joanne Curley
6 Mar 24
4
Ann Michelle Cunningham
6 Mar 24
4
JON S SAXE
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.61 mm | 37.61 mm | 37.61 mm | 37.61 mm | 37.61 mm | 37.61 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.26 mm | 2.98 mm | 2.06 mm | 2.62 mm |
Cash used (since last report) | n/a | n/a | 12.72 mm | 16.78 mm | 11.61 mm | 14.77 mm |
Cash remaining | n/a | n/a | 24.89 mm | 20.83 mm | 26.00 mm | 22.84 mm |
Runway (months of cash) | n/a | n/a | 11.0 | 7.0 | 12.6 | 8.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 4 |
Closed positions | 56 |
Increased positions | 1 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 1.50 bn |
Total shares | 47.96 mm |
Total puts | 0.00 |
Total calls | 14.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners II | 20.70 mm | $26.49 mm |
Growth Equity Opportunities 17 | 16.30 mm | $35.05 mm |
Rosalind Advisors | 5.38 mm | $10.43 mm |
Lincoln Park Capital Fund | 4.61 mm | $3.68 mm |
Vanguard | 223.91 k | $418.72 mm |
Gsa Capital Partners | 198.82 k | $372.00 k |
BLK Blackrock | 105.01 k | $196.36 mm |
Millennium Management | 101.07 k | $189.00 mm |
Geode Capital Management | 57.32 k | $107.19 mm |
GS Goldman Sachs | 57.32 k | $107.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Mary L. Rotunno | Stock Option Common Stock | Grant | Acquire A | No | No | 4.85 | 12,500 | 60.62 k | 12,500 |
4 Mar 24 | Gin Jerry B | Stock Option Common Stock | Grant | Acquire A | No | No | 4.85 | 12,500 | 60.62 k | 12,500 |
4 Mar 24 | Margaret M FitzPatrick | Stock Option Common Stock | Grant | Acquire A | No | No | 4.85 | 12,500 | 60.62 k | 12,500 |
4 Mar 24 | Joanne Curley | Stock Option Common Stock | Grant | Acquire A | No | No | 4.85 | 12,500 | 60.62 k | 12,500 |
4 Mar 24 | Cunningham Ann Michelle | Stock Option Common Stock | Grant | Acquire A | No | No | 4.85 | 12,500 | 60.62 k | 12,500 |
News
10 Health Care Stocks Whale Activity In Today's Session
19 Feb 24
VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
13 Feb 24
Recap: Vistagen Therapeutics Q3 Earnings
13 Feb 24
Earnings Scheduled For February 13, 2024
13 Feb 24
VistaGen Therapeutics's Earnings: A Preview
12 Feb 24
Press releases
Vistagen to Present at Stifel 2024 Virtual CNS Days
11 Mar 24
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
28 Feb 24
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
13 Feb 24
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
6 Feb 24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
27 Dec 23